Myovant Sciences Stock Forecast, Price & News

Myovant Sciences (NYSE:MYOV) Frequently Asked Questions

Is Myovant Sciences a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Myovant Sciences in the last twelve months. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Myovant Sciences stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MYOV, but not buy additional shares or sell existing shares.
View analyst ratings for Myovant Sciences or view top-rated stocks.

How has Myovant Sciences' stock price been impacted by Coronavirus?

Myovant Sciences' stock was trading at $8.70 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MYOV shares have increased by 69.3% and is now trading at $14.73.
View which stocks have been most impacted by COVID-19.

Are investors shorting Myovant Sciences?

Myovant Sciences saw a increase in short interest in the month of December. As of December 15th, there was short interest totaling 4,950,000 shares, an increase of 31.3% from the November 30th total of 3,770,000 shares. Based on an average daily trading volume, of 625,600 shares, the short-interest ratio is currently 7.9 days. Approximately 12.2% of the shares of the company are sold short.
View Myovant Sciences' Short Interest.

When is Myovant Sciences' next earnings date?

Myovant Sciences is scheduled to release its next quarterly earnings announcement on Wednesday, January 26th 2022.
View our earnings forecast for Myovant Sciences.

How can I listen to Myovant Sciences' earnings call?

Myovant Sciences will be holding an earnings conference call on Wednesday, January 26th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Myovant Sciences' earnings last quarter?

Myovant Sciences Ltd. (NYSE:MYOV) posted its earnings results on Tuesday, October, 26th. The company reported ($0.23) EPS for the quarter, beating the Zacks' consensus estimate of ($0.34) by $0.11. The company earned $77.90 million during the quarter, compared to analyst estimates of $72.67 million. During the same quarter in the prior year, the company earned ($0.75) EPS.
View Myovant Sciences' earnings history.

What price target have analysts set for MYOV?

5 brokers have issued 12 month price objectives for Myovant Sciences' shares. Their forecasts range from $18.00 to $32.00. On average, they expect Myovant Sciences' stock price to reach $23.75 in the next year. This suggests a possible upside of 61.2% from the stock's current price.
View analysts' price targets for Myovant Sciences or view top-rated stocks among Wall Street analysts.

Who are Myovant Sciences' key executives?

Myovant Sciences' management team includes the following people:

• David C. Marek, Chief Executive Officer & Director
• Jeffrey D. Nornhold, Senior VP-Pharmaceutical Operations & Development
• Uneek Mehra, Chief Financial & Business Officer
• Juan Camilo Arjona Ferreira, Chief Medical Officer
• Matthew Lang, Secretary, Chief Administrative & Legal Officer (LinkedIn Profile)

Who are some of Myovant Sciences' key competitors?

Some companies that are related to Myovant Sciences include Perrigo (PRGO), HUTCHMED (HCM), Zai Lab (ZLAB), Ultragenyx Pharmaceutical (RARE), Blueprint Medicines (BPMC), Ionis Pharmaceuticals (IONS), CureVac (CVAC), Alkermes (ALKS), Cerevel Therapeutics (CERE), Galapagos (GLPG), Arvinas (ARVN), ACADIA Pharmaceuticals (ACAD), Apellis Pharmaceuticals (APLS), Karuna Therapeutics (KRTX) and Intra-Cellular Therapies (ITCI).
View all of MYOV's competitors.

What other stocks do shareholders of Myovant Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Myovant Sciences investors own include Sorrento Therapeutics (SRNE), Pfizer (PFE), Amarin (AMRN), Inovio Pharmaceuticals (INO), Coty (COTY), Gilead Sciences (GILD), Micron Technology (MU), VBI Vaccines (VBIV), NVIDIA (NVDA) and Carnival Co. & (CCL).

When did Myovant Sciences IPO?

(MYOV) raised $176 million in an initial public offering (IPO) on Thursday, October 27th 2016. The company issued 13,000,000 shares at $12.00-$15.00 per share. Citigroup, Cowen and Company, Evercore ISI and Barclays served as the underwriters for the IPO and JMP Securities and Baird were co-managers.

What is Myovant Sciences' stock symbol?

Myovant Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "MYOV."

How do I buy shares of Myovant Sciences?

Shares of MYOV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Myovant Sciences' stock price today?

One share of MYOV stock can currently be purchased for approximately $14.73.

How much money does Myovant Sciences make?

Myovant Sciences has a market capitalization of $1.37 billion and generates $59.32 million in revenue each year. The company earns $-255.13 million in net income (profit) each year or ($2.61) on an earnings per share basis.

How many employees does Myovant Sciences have?

Myovant Sciences employs 407 workers across the globe.

What is Myovant Sciences' official website?

The official website for Myovant Sciences is www.myovant.com.

Where are Myovant Sciences' headquarters?

Myovant Sciences is headquartered at 11-12 ST. JAMES SQUARE SUITE 1 3RD FLOOR, LONDON X0, SW1Y 4LB.

How can I contact Myovant Sciences?

Myovant Sciences' mailing address is 11-12 ST. JAMES SQUARE SUITE 1 3RD FLOOR, LONDON X0, SW1Y 4LB. The company can be reached via phone at 442074003351 or via email at [email protected].